Scandion Oncology A/S

Equities

SCOL

DK0061031895

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 10:18:54 2024-05-30 am EDT			5-day change	1st Jan Change
0.7 ^SEK	+5.42%		-41.18%	-82.48%

May. 22	Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024
May. 22	Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Scandion Oncology A/S Appoints Maj Hedtjärn as New COO and Head of R&D Operations

April 21, 2021 at 04:19 am EDT

Scandion Oncology A/S announced the appointment of Maj Hedtjärn as new COO and Head of R&D operations. Hedtjärn is the latest addition to the company's executive leadership team, and her extensive experience within R&D operations is an excellent fit for Scandion Oncology, which is aiming to build value as a clinical stage company.

Latest news about Scandion Oncology A/S

Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024	May. 22
Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 22	CI
Transcript : Scandion Oncology A/S - Special Call	May. 15
Scandion Confirms Positive Final Phase Ib Data from Pantax Trial with Sco-101	May. 13	CI
Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival	Mar. 21	CI
Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial	Mar. 07	CI
Transcript : Scandion Oncology A/S, Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Scandion Oncology A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Scandion Oncology A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Transcript : Scandion Oncology A/S - Special Call	Feb. 05
Scandion Oncology Reports Positive Topline Phase IIa Data from the CORIST Part 3 Trial	Jan. 31	CI
Scandion Oncology Receives Notice of Allowance for Patent to Enhance US Patent Exclusivity on SCO-101	Jan. 05	CI
Scandion Oncology Announces Presenting Topline Data in the Ongoing Corist Part 3 Study	Dec. 21	CI
Scandion Oncology Completes Pre-Clinical Studies and Identifies Potentially Effective Treatment of Gastric Cancer	Dec. 15	CI
Scandion Oncology Obtains Patent for Combination Cancer Treatment Drug	Nov. 29	MT
Transcript : Scandion Oncology A/S, Nine Months 2023 Earnings Call, Nov 22, 2023	Nov. 22
Scandion Oncology A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Scandion Oncology Announces Positive Data from Part 2 of its International Multi-Center CORIST Open Label Phase IIa Trial	Nov. 21	CI
Scandion Oncology Successfully Completes Phase Ib Pantax Trial Is and Establishes the Maximal Tolerated Dose with Positive Safety Profile and Pharmacokinetic Data	23-10-15	CI
Scandion Oncology A/S Appoints Lars Damstrup, MD, PhD, as Chief Medical Officer	23-09-12	CI
Transcript : Scandion Oncology A/S, Q2 2023 Earnings Call, Aug 23, 2023	23-08-23
Scandion Oncology A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Scandion Oncology A/S Announces Data from PANTAX Trial to Be Presented At ESMO Congress 2023	23-08-17	CI
The European Patent Office Announces Intention to Grant of Composition-Of-Matter Patent for Scandion Oncology's Lead Compound SCO-101	23-07-18	CI
Transcript : Scandion Oncology A/S, Q1 2023 Earnings Call, May 26, 2023	23-05-26

Chart Scandion Oncology A/S

Duration

Period

More charts

Company Profile

Scandion Oncology A/S is a manufacturer of biological products. The Company was founded in May 2017 and is located in Copenhagen, Denmark. It focuses on modern onclogy, the treatment of cancers that have developed resistance to chemotherapy.

Sector

Biotechnology & Medical Research

Calendar

2024-08-28 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SCANDION ONCOLOGY A/S	-82.48%	2.54M
VERTEX PHARMACEUTICALS INCORPORATED	+8.92%	114B
REGENERON PHARMACEUTICALS, INC.	+10.48%	104B
ARGENX SE	-1.83%	22.57B
BIONTECH SE	-6.45%	22.5B
GENMAB A/S	-10.39%	17.95B
WUXI APPTEC CO., LTD.	-42.36%	16.48B
BEIGENE, LTD.	-14.45%	15.82B
NEUROCRINE BIOSCIENCES, INC.	+3.76%	13.55B
SAREPTA THERAPEUTICS, INC.	+28.94%	10.99B

Bio Therapeutic Drugs